Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Neurology

The Hunt for the Cause: Why Doctors Screen for Cancer

At a Glance

Autoimmune limbic encephalitis (ALE) is often triggered by a hidden tumor. Doctors screen for cancer because treating the underlying tumor is the most effective way to stop the immune system from mistakenly attacking the brain. Based on your antibody type, this screening may continue for up to 5 years.

When a patient is diagnosed with autoimmune limbic encephalitis (ALE), doctors often begin what is known as “the hunt.” This is a thorough search for a hidden, or occult, tumor elsewhere in the body [1][2].

This search is necessary because ALE is often a paraneoplastic syndrome—a condition where the immune system, in its attempt to attack a small cancer, accidentally attacks healthy brain cells that happen to look like the tumor [3][1]. Finding and treating the tumor is often the single most important step in stopping the attack on the brain [4][5].

Why the “Hunt” is Required

Even if you have no typical signs of cancer (like weight loss or pain), the immune system may have already detected a tumor that is too small to cause symptoms [6]. For certain antibody types, the link to cancer is so strong that doctors will continue to look for years even if the first tests are clear [7].

Antibody-Specific Tumor Links

The type of antibody found in your blood or spinal fluid tells the doctors exactly where to focus their search:

  • Anti-Hu and Anti-CV2: These are “high-risk” markers strongly linked to Small Cell Lung Cancer (SCLC) [8][9].
  • Anti-NMDAR: Frequently linked to an ovarian teratoma (a type of germ cell tumor) in young women [4][10].
  • Anti-Ma2: Often points to testicular tumors in younger men, or lung/breast tumors in older patients [11][12].
  • Anti-LGI1: This antibody has a much lower link to cancer, though doctors will still perform a baseline screening to be safe [13][14].

Imaging Modalities: Tools of the Hunt

Doctors use different types of scans to leave no stone unturned:

  • CT Scan (Chest/Abdomen/Pelvis): Usually the first step to look for larger masses [1].
  • FDG-PET/CT: This is a more sensitive scan that uses a radioactive sugar tracer to find “hot spots” of high metabolic activity, which can pinpoint tiny tumors that a regular CT might miss [2][15].
  • Specialized Ultrasound: For women, a transvaginal ultrasound is used to look closely at the ovaries [16][17]. For men, a scrotal ultrasound is used to check the testicles [12].

The Long-Term Watch

If the initial “hunt” comes up empty, the search is not necessarily over. For high-risk markers (like Hu or Ma2), consensus guidelines recommend repeat screening every 6 to 12 months for up to 5 years [7][18]. This is because the neurological symptoms can sometimes appear months or even years before the tumor is large enough to be seen on a scan [7].

Managing the Anxiety

It is completely normal to feel “scanxiety”—the intense stress of waiting for results or undergoing repeated screenings. Remember that finding a tumor early is actually a positive step; it provides a clear target for treatment, which often leads to the best possible recovery for the brain [5][19]. Your care team should provide support to help you manage the emotional weight of this process.

Common questions in this guide

Why do doctors look for cancer if my diagnosis is in the brain?
ALE is often a paraneoplastic syndrome, meaning your immune system is attacking your brain in response to a hidden tumor. Finding and treating this tumor is the most important step in stopping the autoimmune attack on your brain cells.
How does the type of ALE antibody affect my cancer screening?
The specific antibody found in your blood or spinal fluid acts like a map, telling doctors exactly where to look. For example, Anti-Hu points to lung cancer, while Anti-NMDAR often indicates an ovarian teratoma.
What happens if my first cancer scans are clear?
If your first scans are clear but you have high-risk antibodies, doctors will continue to screen you every 6 to 12 months for up to 5 years. This is because neurological symptoms can appear months or years before a tumor is large enough to show up on a scan.
What kind of imaging tests will I need to find the hidden tumor?
You will likely start with a CT scan of your chest, abdomen, and pelvis. If that is clear, doctors may use a highly sensitive FDG-PET/CT scan to look for tiny tumors, along with specialized ultrasounds of the ovaries or testicles.
Will finding a tumor change how my encephalitis is treated?
Yes. Finding and treating the underlying tumor removes the trigger for the immune system's attack. This provides a clear target for treatment and often leads to the best possible neurological recovery.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the specific antibody identified, what is the statistical likelihood that a hidden tumor is causing my symptoms?
  2. 2.If my initial CT scan was negative, should we proceed to an FDG-PET/CT scan for a more detailed look?
  3. 3.Which specific areas (e.g., ovaries, lungs, or testicles) require extra focus or specialized imaging like an ultrasound?
  4. 4.What is the long-term plan for 'repeat screening' if we don't find anything today? How many years will we continue to look?
  5. 5.How does finding and treating a tumor change my neurological recovery plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.

    Graus F, Vogrig A, Muñiz-Castrillo S, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2021; (8(4)) doi:10.1212/NXI.0000000000001014.

    PMID: 34006622
  2. 2

    Additional Value of [18F]FDG PET/CT in Detection of Suspected Malignancy in Patients with Paraneoplastic Neurological Syndromes Having Negative Results of Conventional Radiological Imaging.

    Opalińska M, Sowa-Staszczak A, Wężyk K, et al.

    Journal of clinical medicine 2022; (11(6)) doi:10.3390/jcm11061537.

    PMID: 35329862
  3. 3

    Clinical approach to diagnosis of paraneoplastic neurologic syndromes.

    Graus F

    Handbook of clinical neurology 2024; (200()):79-96 doi:10.1016/B978-0-12-823912-4.00007-4.

    PMID: 38494298
  4. 4

    Autoimmune encephalitis: A diagnostic enigma.

    Nathani M, Singh V, Sharma A, et al.

    Indian journal of medical microbiology 2023; (46()):100477 doi:10.1016/j.ijmmb.2023.100477.

    PMID: 37742479
  5. 5

    Surgical outcomes in patients with anti-N-methyl D-aspartate receptor encephalitis with ovarian teratoma.

    Dai Y, Zhang J, Ren H, et al.

    American journal of obstetrics and gynecology 2019; (221(5)):485.e1-485.e10 doi:10.1016/j.ajog.2019.05.026.

    PMID: 31128109
  6. 6

    Paraneoplastic neurological syndromes: clinical presentations and management.

    Devine MF, Kothapalli N, Elkhooly M, Dubey D

    Therapeutic advances in neurological disorders 2021; (14()):1756286420985323 doi:10.1177/1756286420985323.

    PMID: 33796141
  7. 7

    Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis.

    Villagrán-García M, Farina A, Muñiz-Castrillo S, et al.

    Brain communications 2023; (5(5)):fcad247 doi:10.1093/braincomms/fcad247.

    PMID: 37794924
  8. 8

    Clinical characteristics of paraneoplastic neurological syndrome related to different pathological lung cancers.

    Ma J, Wang A, Jiang W, et al.

    Thoracic cancer 2021; (12(16)):2265-2270 doi:10.1111/1759-7714.14070.

    PMID: 34242487
  9. 9

    Anti-CV2/Collapsin Response Mediator Protein 5 (CRMP5) Paraneoplastic Encephalitis Induced by Small Cell Lung Cancer.

    Helgason VÞ, Qureshi PAAA, Bollineni VR, et al.

    Cureus 2023; (15(1)):e34323 doi:10.7759/cureus.34323.

    PMID: 36865958
  10. 10

    Four-year-old anti-N-methyl-D-aspartate receptor encephalitis patient with ovarian teratoma: A case report.

    Xue CY, Dong H, Yang HX, et al.

    World journal of clinical cases 2021; (9(19)):5319-5324 doi:10.12998/wjcc.v9.i19.5319.

    PMID: 34307584
  11. 11

    Anti-Ma and anti-Ma2-associated paraneoplastic neurological syndromes.

    Ortega Suero G, Sola-Valls N, Escudero D, et al.

    Neurologia 2018; (33(1)):18-27 doi:10.1016/j.nrl.2016.05.010.

    PMID: 27460184
  12. 12

    A Case of Anti-Ma2 Encephalitis Presenting with Pendular Torsional Nystagmus.

    Vaghi G, Vegezzi E, Bini P, et al.

    Cerebellum (London, England) 2024; (23(3)):1249-1253 doi:10.1007/s12311-023-01601-w.

    PMID: 37848701
  13. 13

    Overview of Paraneoplastic Autoantibody-Mediated Cognitive Impairment and Behavioral Changes: A Narrative Review.

    Alkhayat D, Khawaji ZY, Sunyur AM, et al.

    Cureus 2024; (16(1)):e51787 doi:10.7759/cureus.51787.

    PMID: 38322089
  14. 14

    [Paraneoplastic neurologic syndromes: laboratory diagnostics and immunological aspects].

    Hayden Z, Böröcz K, Csizmadia Z, et al.

    Magyar onkologia 2019; (63(3)):261-267.

    PMID: 31533147
  15. 15

    Imaging for the Pretreatment Staging of Small cell Lung Cancer: A Systematic Review.

    Mitchell MD, Aggarwal C, Tsou AY, et al.

    Academic radiology 2016; (23(8)):1047-56.

    PMID: 27259379
  16. 16

    Anti-N-methyl-D-aspartate receptor encephalitis with an imaging-invisible ovarian teratoma: a case report.

    Abdul-Rahman ZM, Panegyres PK, Roeck M, et al.

    Journal of medical case reports 2016; (10(1)):296 doi:10.1186/s13256-016-1067-4.

    PMID: 27776544
  17. 17

    Anti-NMDA receptor encephalitis in an adolescent with a cryptic ovarian teratoma.

    Walker CA, Poulik J, D'Mello RJ

    BMJ case reports 2021; (14(7)) doi:10.1136/bcr-2020-236340.

    PMID: 34230042
  18. 18

    Anti-N-methyl-d-aspartate receptor encephalitis: A primer for acute care healthcare professionals.

    Anderson D, Nathoo N, McCombe JA, et al.

    Journal of the Intensive Care Society 2021; (22(2)):95-101 doi:10.1177/1751143720914181.

    PMID: 34025748
  19. 19

    Ovarian teratoma-associated anti-NMDAR encephalitis: a single-institute series of six patients from China.

    Yu M, Li S, Cheng J, et al.

    Archives of gynecology and obstetrics 2021; (303(5)):1283-1294 doi:10.1007/s00404-020-05861-3.

    PMID: 33216164

This page explains cancer screening protocols for autoimmune limbic encephalitis for educational purposes. Always consult your neurology and oncology teams regarding your specific test results and screening schedule.

Get notified when new evidence is published on Autoimmune limbic encephalitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.